Methods of using low-dose doxepin for the improvement of sleep

Abstract

Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).

Description

RELATED APPLICATIONS[0001]This application is a continuation of application Ser. No. 11 / 804,720, filed May 18, 2007, which claims priority under 35 U.S.C. 119(e) to U.S. Provisional Application Nos. 60 / 801,824, filed May 19, 2006; and 60 / 833,319, filed Jul. 25, 2006, the entire contents of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to the use of low doses of doxepin (e.g., 1-6 milligrams) to improve sleep, including sleep efficiency and early awakening in an individual.BACKGROUND OF THE INVENTION[0003]Sleep is essential for health and quality of life. Insomnia is a growing health problem in the United States. It is believed that more than 10-15 million people suffer from chronic insomnia and up to an additional 70 million people suffer from some form of insomnia each year. Insomnia is a condition characterized by difficulty falling asleep (sleep onset), waking frequently during the night (fragmented sleep), waking too early (...

AI Technical Summary

Benefits of technology

"The patent text describes methods for reducing or preventing early awakenings and fragmented sleep in patients with sleep disorders. The methods involve administering doxepin, a pharmaceutically acceptable salt or prodrug thereof, to the patient prior to the sleep period. The dosage of doxepin can range from 1 milligram to 6 milligrams and can be effective in lengthening the sleep period or reducing wake time after sleep. The methods can be used for patients with chronic or non-chronic insomnia or transient insomnia."

Problems solved by technology

Insomnia is a growing health problem in the United States.

Although there have been several advances in pharmaceutical treatments for insomnia, it is often hard to find an ideal drug for treating particular forms of insomnia.

One common problem is early termination of sleep or premature final awakening.

For example, many individuals may wake prematurely and not fall back asleep, thereby failing to achieve a full night of sleep.

Many drugs that are effective in inducing or expediting sleep initiation do not provide much effect in maintaining sleep, particularly through the eighth and final hour of sleep period.

Drugs that are sufficiently powerful to induce a full eight hours sleep often cause serious hangover effects, i.e., the patient has difficulty awakening and / or feels sedated, sleepy, or disoriented and may demonstrate impairment of psychomotor function.

In addition to patients having difficulty with early termination of sleep during the last 60, 90, or 120 minutes of an 8 hour sleep period, other patients have problems with fragmented or disrupted sleep.

However, prior to the present invention, doxepin was not known to have particular efficacy in treating premature termination of sleep at the end of an 8 hour sleep period, nor was it known to be efficacious in treating those patients with disturbed sleep patterns during the final 60, 90, or 120 minutes of an 8-hour sleep period.

As a result, it would be expected that dosages of doxepin that are sufficient to address premature final awakenings or last-hour sleep efficiency in the elderly would also cause post-sleep sedation or other undesirable side effects.

Images